Telephone: 61-02-93822614; Fax: 61-02-93822629
Translational and Clinical Research
Version of Record online: 13 JUL 2010
Copyright © 2010 AlphaMed Press
Volume 28, Issue 9, pages 1686–1702, September 2010
How to Cite
Tang, C., Russell, P. J., Martiniello-Wilks, R., J. Rasko, J. E. and Khatri, A. (2010), Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?. STEM CELLS, 28: 1686–1702. doi: 10.1002/stem.473
Author contribution: C.T.: literature searches and review, manuscript writing; P.J R.: financial support (Grant funds), manuscript writing and revision; R.M.: literature searches and review, edited the manuscript; J.E.R.: edited the manuscript; A.K.: literature searches and review, manuscript writing, revisions and financial support (Grant funds).
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLS EXPRESS July 13, 2010.
- Issue online: 13 JUL 2010
- Version of Record online: 13 JUL 2010
- Manuscript Accepted: 11 JUN 2010
- Manuscript Received: 5 NOV 2009
- Cancer Australia Prioritydriven Collaborative Cancer Research Scheme, Prostate Cancer Foundation, Australia and University of New South Wales Faculty Research Grants Funding Scheme, Australia.
- Stem cell tracking and imaging;
- Magnetic nanoparticles;
- Mesenchymal stem cells;
- Gene therapy;
Ineffective treatment and poor patient management continue to plague the arena of clinical oncology. The crucial issues include inadequate treatment efficacy due to ineffective targeting of cancer deposits, systemic toxicities, suboptimal cancer detection and disease monitoring. This has led to the quest for clinically relevant, innovative multifaceted solutions such as development of targeted and traceable therapies. Mesenchymal stem cells (MSCs) have the intrinsic ability to “home” to growing tumors and are hypoimmunogenic. Therefore, these can be used as (a) “Trojan Horses” to deliver gene therapy directly into the tumors and (b) carriers of nanoparticles to allow cell tracking and simultaneous cancer detection. The camouflage of MSC carriers can potentially tackle the issues of safety, vector, and/or transgene immunogenicity as well as nanoparticle clearance and toxicity. The versatility of the nanotechnology platform could allow cellular tracking using single or multimodal imaging modalities. Toward that end, noninvasive magnetic resonance imaging (MRI) is fast becoming a clinical favorite, though there is scope for improvement in its accuracy and sensitivity. In that, use of superparamagnetic iron-oxide nanoparticles (SPION) as MRI contrast enhancers may be the best option for tracking therapeutic MSC. The prospects and consequences of synergistic approaches using MSC carriers, gene therapy, and SPION in developing cancer diagnostics and therapeutics are discussed. STEM CELLS 2010; 28:1686–1702.